MAPT and tauopathy: Lastly, we retrospectively assessed CSF MTBR-tau275/t-tau and MTBR-tau282/t-tau by final clinical syndromes in a neuropathologically confirmed cohort to determine if these biomarkers can facilitate antemortem diagnosis of primary tauopathies.